TCTamara Castillo-Triviño

Tamara Castillo-Triviño

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tamara Castillo-Triviño has a total of 511 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessing the influence of biological sex and pregnancy on disability of multiple sclerosis patients

    by Farzana Jahan, Insha Ullah, Vilija Jokubaitis, Helmut Butzkueven, Francesco Patti, Bianca Weinstock-Guttman, Valentina Tomassini, Alessandra Lugaresi, Tomas Kalincik, Samia J Khoury, et al.

    Background and objectives: Biological sex, hormonal influences and pregnancy-related immune changes may affect disability progression in multiple sclerosis (MS), but large longitudinal evidence is limited. This study examined the association between sex, pregnancy history and disability using MSBase registry data. Methods: Data from 537,582 visits across 16 countries were analysed, with 1–126 visits per patient. Disability was measured using the Expanded Disability Status Scale (EDSS), modelled as a standardised z-score. Hierarchical generalised additive mixed models were fitted separately by country, adjusting for confounders, with pooled estimates from random-effects meta-analysis. Analyses compared (1) males vs females and (2) males, females ever pregnant and females never pregnant (reference). Results: Males were associated with higher disability than females (95% CI: 0.103,0.184). In the three-group model, males were associated with higher disability (95% CI: 0.036, 0.146), while females with a history of pregnancy were associated with lower disability (95% CI: −0.238,−0.108) compared with females who had never been pregnant. Differences corresponded to approximately 0.2–0.4 EDSS points, indicating relatively modest differences in absolute disability. Conclusions: Biological sex and pregnancy history were associated with MS disability. Although modest, these differences may accumulate over time, suggesting reproductive history is an important factor in MS outcomes, but one cannot make any causal interpretation from these results.

  • Open Access

    XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part II)

    by Óscar Fernández, Xavier Montalban, Adrián Arés, Eduardo Agüera, Yolanda Aladro, Ana Alonso, Rafael Arroyo, Luis Brieva, Carmen Calles, Ana Belén Caminero, et al.

    The 18th edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 17–18 October 2025 in Madrid, bringing together Spanish neurologists specialising in multiple sclerosis (MS), who presented the most relevant advances discussed at the ECTRIMS congress held a few days earlier in Barcelona. The aim of this edition was to present the latest developments in MS regarding the update of diagnostic criteria, advanced neuroimaging techniques, the role of Epstein-Barr virus, remyelination mechanisms and biomarkers. In the therapeutic field, emerging treatments were addressed, such as new monoclonal antibodies and chimeric antigen receptor T cells (CAR-T), the management of elderly patients and the risks associated with high-efficacy therapies. This article is the second of a two-part series (I and II). The article reviews recent data on disease progression and on the concept of progression independent of relapse activity (PIRA), including the definition, among those published, that leads to balanced incidence and persistence in PIRA rates. Certain neuropathological and imaging aspects are reviewed, and, with regard to serum biomarkers, it is emphasised that neurofilament light chain (NfL) is a marker of acute damage that is not specific to MS, and that the challenge lies in establishing a value that differentiates it from other diseases. It is also discussed whether the low sensitivity of NfL for predicting progression lies in the z-score used in clinical practice, and the usefulness of glial fibrillary acidic protein (GFAP) in combination with NfL to refine the assessment of chronic progressive damage. The importance of age in MS is indisputable. The elderly patient with MS has a greater number of comorbidities and is more vulnerable to certain treatments. Menopause is a normal but expected physiological transition of female ageing that may trigger or aggravate certain health problems, and whose symptoms should not be confused with worsening of the disease. As for cognitive impairment in MS, the latest developments and expert opinions that could help improve its identification and monitoring are summarised. Much of this part II article focuses on summarising the key advances in emerging therapies and treatment prospects in related diseases, without overlooking the risks associated with very high-efficacy therapies and the possible risk-prevention strategies. Finally, as important findings that translate into clinical practice, the notable improvement in diagnosis with the new 2024 McDonald criteria stands out, despite the barriers to accessing paraclinical tests in certain populations. Overall, the data reviewed, together with those gathered in part I, reflect the research effort to advance the understanding of the disease from multiple complementary perspectives, which is transforming the care of patients with MS.

  • Open Access

    XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part I)

    by Óscar Fernández, Xavier Montalban, Adrián Arés, Eduardo Agüera, Yolanda Aladro, Ana Alonso, Rafael Arroyo, Luis Brieva, Carmen Calles, Ana Belén Caminero, et al.

    The 18th edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 17–18 October 2025 in Madrid, bringing together Spanish neurologists specialising in multiple sclerosis (MS), who presented the most relevant advances discussed at the ECTRIMS congress held a few days earlier in Barcelona. The aim of the meeting was to summarise the latest developments in the pathogenesis, new diagnostic criteria and biomarkers of MS. This article is the first of a two-part series (I and II) that reviews recent data on cell trafficking into the central nervous system, highlighting the functional heterogeneity of the brain endothelium, the molecular mechanisms regulating leukocyte infiltration and the differential role of macrophages and resident microglia in tissue damage and chronic inflammation. The evidence supporting the role of Epstein-Barr virus as a necessary risk factor in MS is presented, together with the therapeutic and preventive implications from studies of antiviral therapies, cell-based therapies and vaccines. Regarding diagnosis, the new criteria for neuromyelitis optica spectrum disorders are addressed, with particular attention to the molecular heterogeneity of double-seronegative forms, as well as the update of the magnetic resonance imaging (MRI) guidelines following the 2024 revision of the McDonald criteria. Advances in the neuroimaging of chronic active inflammation, quantitative spinal cord imaging and the concept of spinal cord reserve are highlighted. The growing role of artificial intelligence applied to MRI for the early prediction of progression and treatment response is also reviewed. Finally, advances in remyelination mechanisms and in biomarkers are presented, underscoring the value of multimodal and longitudinal approaches for prognostic stratification and treatment monitoring. Overall, the data reviewed reflect a change into a more integrated and predictive understanding of MS, with direct implications for early diagnosis, treatment personalisation and the design of future clinical trials.

  • Open Access

    Causal effects of multiple sclerosis therapies in left-truncated registry data

    by Dagmawi Chilot Haile, Ibrahima Diouf, Serkan Ozakbas, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Sara Eichau, Raed Alroughani, Alessandra Lugaresi, Valentina Tomassini, et al.

    Background: Left-truncation is an unrecorded interval between multiple sclerosis (MS) onset and initial data in observational studies. This delay may bias estimates of disease-modifying therapy (DMT) effectiveness, especially when determined by patient or disease characteristics. Objectives: To examine whether causal effect estimates of DMTs over the full disease course can be reliably derived from left-truncated registry data. Methods: We analysed data from MSBase (144 centres, 41 countries) to assess the impact of left-truncation on causal treatment effect estimates. Cox marginal structural models (MSMs) estimated hazard ratios (HRs) for relapses, disability worsening and improvement, considering left-truncation at random and not-at-random. Fixed-time truncation and multivariable adjustment were applied to remediate bias. Results: The study included 5588 patients tracked from true MS onset. The null model, without left-truncation, estimated the DMT effect on relapse risk (HR = 0.64; 95% confidence interval (CI) = 0.54–0.77). Left-truncation inflated this estimate. Shorter random truncation (1 year) produced greater bias (HR = 0.34), decreasing with longer durations (3-year HR = 0.48). Truncation not-at-random biased relapse estimates (HR = 0.37). Disability outcomes were less sensitive. Conclusion: MSMs can reliably estimate DMT effectiveness in left-truncated MS registry data, although accuracy depends on truncation mechanism and duration. Both random and not-at-random truncation impact relapse estimates. Disability outcomes appear less sensitive. Fixed-time truncation and covariate adjustment mitigated bias.

  • Open Access

    A dual-function variant on chromosome 17 regulates circRNA expression and splicing in multiple sclerosis

    by Saioa Gs Iñiguez, Leire Iparraguirre, Eduardo Andrés-León, Hirune Crespillo, Leire Romarate, Tamara Castillo Triviño, Elena Urcelay, Manuel Comabella, Sunny Malhotra, Xavier Montalban, et al.

    Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system with a complex etiology. Recent genomic studies highlight the contribution of expression quantitative trait loci (eQTLs) in modulating gene expression and disease susceptibility. Given the emerging role of circular RNAs (circRNAs) in MS, we hypothesized that genetic variants may regulate circRNA expression through circRNA-specific eQTLs (circ-eQTLs). We performed a cis -circ-eQTL analysis integrating circRNA expression and whole-genome genotyping data from 30 MS patients and 18 healthy controls using a linear regression model adjusted for disease status and sex. Candidate circ-eQTLs were prioritized based on MS-associated regions and known splicing QTLs (sQTLs) from GTEx and validated in an independent cohort (67 MS, 64 controls). Association analysis in a larger cohort (2831 MS, 3191 controls) evaluated two candidate variants for MS risk. We identified 42,077 significant cis -circ-eQTLs and validated three. Two SNPs, rs7214410 and rs11079784, modulated hsa_circ_0106983 expression, and rs7214410 also acted as an sQTL affecting EFCAB13 splicing. rs7214410 showed stronger association with MS than rs11079784. Our findings reveal extensive genetic regulation of circRNA expression and highlight rs7214410 as a dual-function variant refining the MS susceptibility locus on chromosome 17.


  • Open Access

    Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

    by Cyrus Daruwalla, Courtney Kremler, Francesco Patti, Serkan Ozakbas, Cavit Boz, Jeannette Lechner-Scott, Andrea Surcinelli, Matteo Foschi, Samia J Khoury, Helmut Butzkueven, et al.

    Clinically silent MRI lesions occur frequently in people with relapsing-remitting multiple sclerosis (RRMS) despite disease modifying therapy (DMT). Guidelines only recommend DMT escalation after multiple silent lesions, and adherence is variable. We explored outcomes and the effect of treatment escalation following single and multiple on-treatment silent lesions. This cohort study and emulated target trial used MSBase registry data from 99 clinics in 26 countries between 2007 and 2025. Clinically stable participants receiving any DMT for RRMS with silent lesions versus without silent lesions were compared. Among participants with silent lesions while taking platform or moderate-efficacy DMTs, outcomes following treatment escalation within 6 months versus no treatment escalation (unless a post-MRI clinical event occurred) were compared. The primary outcome was an MS relapse, and the secondary outcome was 6-month confirmed disability worsening. A total of 10,232 participants met inclusion criteria (71.7% female, mean age 41 [SD 11]). The 2-year cumulative incidence of relapse was 27.8% (95% CI 25.7%-29.9%) in participants with silent lesions versus 14.3% (95% CI 13.5%-15.2%) without (adjusted hazard ratio [aHR] 1.76 [95% CI 1.57-1.97]). The 2-year cumulative incidence of disability worsening was 13.8% (95% CI 12.2%-15.5%) in participants with silent lesions versus 11.4% (95% CI 10.7%-12.2%) without (aHR 1.38 [95% CI 1.18-1.62]). Rates of relapse and disability worsening were higher following single and multiple silent lesions versus no silent lesions. The emulated trial included 2,264 participants with ≥1 silent lesion on platform or moderate efficacy DMTs, 286 of whom escalated DMT within 6 months following silent lesions. The 4-year cumulative incidence of relapse was lower following treatment escalation (16.8% [95% CI 12.4%-23.4%]) versus continuation (38.9% [95% CI 35.8%-42.1%]), aHR 0.34 (95% CI 0.23-0.47), with similar aHRs following single and multiple silent lesions. The 4-year cumulative incidence of disability worsening was similar following treatment escalation (16.0% [95% CI 10.8%-22.2%]) versus continuation (17.7% [95% CI 15.3%-20.1%]), aHR 0.89 (95% CI 0.56-1.33). People with RRMS with single or multiple on-treatment silent MRI lesions have higher subsequent risks of relapse and disability worsening than people without silent lesions. DMT escalation mitigates the relapse risk, though disability worsening continues at a similar rate over 4 years. Contrary to guidelines, DMT escalation should be considered after single or multiple silent lesions.

  • Open Access

    The mediating role of illness perception in the association between psychological distress and symptom reporting in early-stage multiple sclerosis patients

    by Florencia Elena Saposnik, Jorge Maurino, Susana Sainz de la Maza, Angela Kwan, Tamara Castillo-Triviño, Rocío Gómez-Ballesteros


  • Open Access

    Unique Polysomnography Pattern Leading to the Diagnosis of Anti-Ma2 Encephalitis

    by Guillermo Nuñez-Manjarres, Ane Mínguez-Olaondo, Tamara Castillo-Triviño, Ana Vinagre-Aragon, Amaia Muñoz-Lopetegi

    Anti-Ma2 encephalitis is a rare autoimmune paraneoplastic syndrome that can present as secondary narcolepsy due to hypothalamic involvement. We present a case of anti-Ma2 encephalitis in which polysomnography was key to suspect the final diagnosis. A 72-year-old man presented with progressive hypersomnia and recurrent falls, initially misinterpreted as secondary to obstructive sleep apnea and cardiogenic syncope, respectively. Symptoms continued to worsen, prompting hospital admission. Video-polysomnography revealed a previously unreported sleep pattern, characterized by an abnormally increased proportion of REM sleep (approximately 3 times the expected), with sleep-onset REM periods occurring every time sleep was resumed after nocturnal awakenings. In addition, non-REM sleep was undifferentiated, without sleep spindles, K complexes, or slow-wave sleep. The recurrent SOREMPs raised suspicion of secondary narcolepsy. MRI showed T2 hyperintensities in different brain regions, including the hypothalamus, and CSF analysis confirmed anti-Ma2 antibodies and decreased hypocretin-1 levels. Symptoms only partially improved after immunotherapy, and malignancy screening remained inconclusive. This case illustrates the diagnostic challenge of autoimmune encephalitis, especially in the older population, and adds to the growing evidence on the value of sleep studies in these conditions. We describe a unique polysomnography pattern in anti-Ma2 encephalitis that could guide the diagnosis of this entity.


  • Open Access

    Tetraspanins, GLAST and L1CAM Quantification in Single Extracellular Vesicles from Cerebrospinal Fluid and Serum of People with Multiple Sclerosis

    by Rocío Del Carmen Bravo-Miana, Jone Karmele Arizaga-Echebarria, Valeria Sabas-Ortega, Hirune Crespillo-Velasco, Alvaro Prada, Tamara Castillo-Triviño, David Otaegui

    Objective: This study aimed to unravel the single tetraspanin pattern of extracellular vesicles (EVs), L1CAM+ and GLAST+ EV levels as diagnostic biomarkers to stratify people with multiple sclerosis (pwMS), specifically relapsing–remitting (RRMS) and primary progressive (PPMS). Methods: The ExoView platform was used to directly track single EVs using a clinically feasible volume of cerebrospinal fluid (CSF) and serum samples. This technology allowed us to examine the patterns of classical tetraspanin and quantify the levels of L1CAM and GLAST proteins, commonly used to immunoisolate putative neuron- and astrocyte-derived EVs. Results: The tetraspanin EV pattern does not allow us to differentiate RRMS, PPMS and non-MS donors neither in CSF nor serum, but this was associated with the type of biofluid. L1CAM+ and GLAST+ EVs showed a very low presence of tetraspanin proteins. Additionally, a significant decrease in the particle count of L1CAM+ EVs was detected in L1CAM-captured spots, and L1CAM+ and GLAST+ EVs decreased in GLAST-captured spots in the CSF from PPMS subjects compared to RRMS. Interestingly, only GLAST+ EVs exhibited a lower quantity in the CSF from PPMS compared to both MS and non-MS samples. Finally, GLAST+ EVs demonstrated a medium negative and significative correlation with GFAP levels—a biomarker of MS progression, astrocyte damage and neurodegenerative processes. Conclusions: ExoView technology could track neural EV biomarkers and be potentially useful in the diagnostic evaluation and follow-up of pwMS. GLAST+ EVs might provide insights into the etiology of PPMS and could offer small windows to elucidate the molecular mechanisms behind its clinical presentation.


  • Open Access

    Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study

    by Edward De Brouwer, Thijs Becker, Lorin Werthen-Brabants, Pieter Dewulf, Dimitrios Iliadis, Cathérine Dekeyser, Guy Laureys, Bart Van Wijmeersch, Veronica Popescu, Tom Dhaene, et al.

    Background: Disability progression is a key milestone in the disease evolution of people with multiple sclerosis (PwMS). Prediction models of the probability of disability progression have not yet reached the level of trust needed to be adopted in the clinic. A common benchmark to assess model development in multiple sclerosis is also currently lacking. Methods: Data of adult PwMS with a follow-up of at least three years from 146 MS centers, spread over 40 countries and collected by the MSBase consortium was used. With basic inclusion criteria for quality requirements, it represents a total of 15, 240 PwMS. External validation was performed and repeated five times to assess the significance of the results. Transparent Reporting for Individual Prognosis Or Diagnosis (TRIPOD) guidelines were followed. Confirmed disability progression after two years was predicted, with a confirmation window of six months. Only routinely collected variables were used such as the expanded disability status scale, treatment, relapse information, and MS course. To learn the probability of disability progression, state-of-the-art machine learning models were investigated. The discrimination performance of the models is evaluated with the area under the receiver operator curve (ROC-AUC) and under the precision recall curve (AUC-PR), and their calibration via the Brier score and the expected calibration error. All our preprocessing and model code are available at https://gitlab.com/edebrouwer/ms_benchmark, making this task an ideal benchmark for predicting disability progression in MS. Findings: Machine learning models achieved a ROC-AUC of 0⋅71 ± 0⋅01, an AUC-PR of 0⋅26 ± 0⋅02, a Brier score of 0⋅1 ± 0⋅01 and an expected calibration error of 0⋅07 ± 0⋅04. The history of disability progression was identified as being more predictive for future disability progression than the treatment or relapses history. Conclusions: Good discrimination and calibration performance on an external validation set is achieved, using only routinely collected variables. This suggests machine-learning models can reliably inform clinicians about the future occurrence of progression and are mature for a clinical impact study.